|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1982-3-13
|
|
pubmed:abstractText |
We have designed a method for growing bone marrow cells infected with Abelson murine leukemia virus which permits examination of target cell growth early after infection. This culture system increases the efficiency of target cell growth by favoring rapid growth of a mixed population of adherent cells in the primary culture. The nonadherent Abelson virus-infected cell populations expressed pre-B-cell differentiation markers characteristic of Abelson virus-transformed cells (mu-heavy chains of immunoglobulin M and terminal deoxynucleotidyltransferase). Early after infection, these cell populations exhibited restricted in vitro and in vivo growth properties which differed from those of an established Abelson virus-transformed cell line, 2M3. These included a marked dependency upon the adherent cell layer for growth and viability, a lower efficiency of agar colony formation, and a lower capacity for tumor production in syngeneic animals. Growth of the early populations could be maintained in the absence of the adherent cell layer by using conditioned medium from long-term adherent cell cultures established in the absence of viral infection. After passage of the populations for several weeks, the in vitro growth properties gradually shifted toward that of the 2M3 cell line. Twelve-week-old populations grew independently of the adherent cell layer and showed an increased efficiency of agar colony formation. These data indicate that many lymphoid target cells exhibit an intermediate transformed phenotype when infected with Abelson virus. Growth of these cells in culture is mediated via a synergistic interaction between intracellular expression of the viral transforming gene and an exogenous growth-promoting activity which can be provided by cultures of adherent bone marrow cells.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-163444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-168584,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-178822,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-206646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-209468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-211510,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-215207,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-215208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-222460,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-311896,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-317834,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-4318922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-4477018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-5432063,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-543547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6245237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6253168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6253217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6254050,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6257398,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6257926,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6258797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6258798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6933049,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-6933522,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-702054,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6275106-7356645
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
577-84
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:6275106-Abelson murine leukemia virus,
pubmed-meshheading:6275106-Animals,
pubmed-meshheading:6275106-Bone Marrow Cells,
pubmed-meshheading:6275106-Cell Adhesion,
pubmed-meshheading:6275106-Cell Division,
pubmed-meshheading:6275106-Cell Transformation, Neoplastic,
pubmed-meshheading:6275106-Cell Transformation, Viral,
pubmed-meshheading:6275106-Cells, Cultured,
pubmed-meshheading:6275106-Clone Cells,
pubmed-meshheading:6275106-Culture Media,
pubmed-meshheading:6275106-Leukemia, Experimental,
pubmed-meshheading:6275106-Leukemia Virus, Murine,
pubmed-meshheading:6275106-Lymphocytes,
pubmed-meshheading:6275106-Mice,
pubmed-meshheading:6275106-Mice, Inbred BALB C
|
|
pubmed:year |
1981
|
|
pubmed:articleTitle |
Abelson virus-infected cells can exhibit restricted in vitro growth and low oncogenic potential.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
